Read More

Vertex Announces New Drug Submission For Exagamglogene Autotemcel Has Been Accepted For Priority Review By Health Canada For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia

-Exa-cel is the first CRISPR-based gene-edited therapy to be submitted for Health Canada review-TORONTO, April 1, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced its New Drug

VRTX